Preoperative CEA marks poor colorectal cancer prognosis

  • Huang SH & al.
  • Ann Surg Oncol
  • 26 Mar 2019

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Preoperative carcinoembryonic antigen (CEA) levels >10 ng/mL are associated with worse survival in patients with stage I-III colorectal cancer (CRC) undergoing curative-intent resection.
  • 5-year survival was similar between patients with negative lymph node staging and CEA >10 ng/mL and those with positive lymph node staging and CEA ≤5 ng/mL.

Why this matters

  • The results suggest that patients with negative lymph node stage and CEA >10 ng/mL are candidates for intense follow-up and/or adjuvant chemotherapy.

Study design

  • Retrospective propensity-score analysis of 6099 patients with stage I-III CRC.
  • Funding: Chang Gung Medical Research Fund.

Key results

  • A propensity score analysis showed higher mortality associated with higher CEA levels compared with CEA ≤5 ng/mL:
    • CEA 5-10 ng/mL: OS (comparison to CEA ≤5 ng/mL; HR, 1.376), cancer-specific survival (CSS; HR, 1.404), recurrence-free interval (RI; HR, 1.190; P<.01 for all>
    • CEA >10 ng/mL: OS (HR, 1.523), CSS (HR, 1.712), and RI (HR, 1.468; P<.01 for all>
  • Patients with negative lymph node stage and CEA >10 ng/mL and patients with positive lymph node staging and CEA ≤ 5 ng/mL had similar 5-year OS (72% vs 69%; P=.542) and RI (19.9 vs 21.72 months; P=.662).

Limitations

  • Retrospective, single-center analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit